DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
GS-4997 is an investigational drug.
There have been 9 clinical trials for GS-4997. The most recent clinical trial was a Phase 2 trial, which was initiated on January 30th 2017.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Kidney Diseases. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].
There are eleven US patents protecting this investigational drug and one hundred and sixty-five international patents.
Recent Clinical Trials for GS-4997
|Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis||Gilead Sciences||Phase 3|
|Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)||Gilead Sciences||Phase 3|
|GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)||Gilead Sciences||Phase 2|
Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GS-4997||Start Trial||Methods of treating liver disease||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|GS-4997||Start Trial||Apoptosis signal-regulating kinase inhibitors||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|GS-4997||Start Trial||Apoptosis signal-regulating kinase inhibitor||Gilead Sciences, Inc. (Foster City, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|